Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus neoadjuvant chemotherapy versus placebo plus neoadjuvant chemotherapy in high-risk ER-positive, HER2-negative primary breast cancer
2019-002469-37Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Nivolumab arm with Placebo arm (2 arms). Primary endpoint: Pathological complete response rate. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002469-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002469-37.